Summary The “Internet of things” is forecast to become a $7 to $10 trillion market by 2020. Also know as “IoT,” these three letters excite those in the tech field. The riskiest, yet most rewarding investments in the market are…
Free Articles
Public Live Show, Every Friday at 4:15 PM Eastern
I will be live for a free live show today at 4:15 EST. I will be doing this every Friday for market week wrap, questions, whatever u want to talk about, but keep it civil. Personal insults or the like…
Wednesday Afternoon Market Commentary July 23 – $IBB Temp Topping, FB And GILD Beat FOLD Hits
Wednesday Afternoon Market Commentary July 23 – $IBB Temp Topping, FB And GILD Beat, FOLD Hits. $FOLD met first resistance of $4,25, needed to clear $4.30, could not as short hedges protected, might make another run tomorrow where short hedges…
Big Money Has Been Buying Amicus (FOLD)
We bought a few shares of this one, we think decent shot it moves over $4 today One investing strategy in the biotech field is to follow what successful biotech funds are doing. We detailed some companies last year…
AcelRx Should Trend Higher As FDA Approval Is Likely At End Of This Month
Summary AcelRx develops Zalviso to treat acute and breakthrough pain. We believe there is a 90% chance the company receives FDA approval on July 27. Zalviso has several advantages over intravenous delivery methods. Obamacare and favorable product pricing should benefit…
Activist Investor David Callan Has Been Accumulating Identiv Stock, Here is Why
Summary These days we hear about shareholder activism almost daily. It is next to impossible to watch CNBC and not hear discussions about some form of activism. Carl Icahn, Dan Loeb, Bill Ackman, George Soros or any of other…
Updated And Amended: Why Mannkind’s Afrezza Is No Blockbuster And Will Be Rejected By FDA
Updated 6/22: Cleaned up thesis to include that we feel the stock price will tank hard even if Afrezza is approved. Background and Story of Afreza MannKind Corporation (MNKD) is a biopharmaceutical company that focuses on the discovery, development, and…
Updated With Options Activity Reflected: Acquisition Thesis on Volcano Corp.
Note: I’m long here a decent amount of shares in the $18.15’s range. Buy range = $17.98 to $18.20, stop range = $16.99 t0 $17.20. Target opinion range for shorter term swing trade = $20.45. Acquisition target = $23 -…
Research Report And Thesis On Halozyme
Investment Thesis with Halozyme (HALO) and Story: Last year HALO was a one of the high flying biotech stocks, and increased in value 5 x. Much of Halo’s big run occurred when we mentioned that a company director bought 50,000…
Video Market Commentary And Chart Reviews For Monday, June 2 2014 – ECB In Focus
Market Commentary And Chart Reviews For Monday, June 2 2014 – ECB In Focus. $IBB, $PGNX, $QQQ, $SPY, $OREX, $HALO reviewed. ECB meets on Wednesday. Rate cut expected along with minor credit easing. I do not expect any talk of…
